Iroko gets a thumbs-up from FDA on lower-dose NSAID

John Carroll Iroko Pharmaceuticals failed to launch a $ 145 million IPO earlier in the year, but it has managed to win regulatory approval for a lower-dose, nonsteroidal anti-inflammatory ...

1M fake Xanax pills intercepted on their way to Egypt from China

Eric Palmer The regulator says the drugs looked so genuine that they were not initially identified as counterfeit, Bloomberg reports. But tests confirmed they were fakes and now they ...

Medivir Shares Results from Simeprevir

mia.burns Medivir announces data from two phase III studies with Simeprevir in hepatitis C subpopulations – HCV/HIV co-infected and genotype 4 infected patients Stockholm, Sweden ...

Sun to benefit from Doxil shortage, but CEO eyes deals for bigger growth

Tracy Staton With Johnson & Johnson's cancer treatment Doxil expected to run short till the end of 2014, India's Sun Pharmaceutical Industries stands to gain. To meet demand ...

Drugmakers want to block Maine from cheaper Canadian drugs

Eric Palmer What do you think? Would a buyer rather pay $ 200 for a prescription of AstraZeneca's heartburn medicine Nexium, or $ 620? Seems pretty simple, but that math is at ...

Acino agrees to $439M takeover offer from private equity firms

Carly Helfand Swiss drugmaker Acino has agreed to be acquired by Avista Capital Partners and Nordic Capital for 398 million Swiss francs, or about $ 439 million, joining the recent ...

Shutdown looming, FDA approves new depression drug from Lundbeck, Takeda

John Carroll Regulators at the FDA stamped an approval on Brintellix, a new therapy to treat major depression from Lundbeck and Takeda, just hours before the government prepared to ...

Great expectations build for PCSK9 blockbuster prospect from Sanofi, Regeneron

John Carroll In an industry like pharma, you're only as good as your next big Phase III study. And hopes are running very, very high for the first round of late-stage results on ...

HHS Orders $196M in Anthrax Antitoxin From Glaxo

barbara.lempert HHS replenishes nation’s supply of anthrax antitoxin Contracts provide new surge capacity, maintain stockpile for public health emergencies The nation’s ...

EU body endorses 11 new drugs from Glaxo, Roche, J&J and others

Ryan McBride A European Union regulator has recommended approval of 11 new drugs for a range of diseases such as HIV, breast cancer and diabetes. And the nods could lead to final approvals ...

Muscular dystrophy drug from GlaxoSmithKline, Prosensa fails PhIII

John Carroll GlaxoSmithKline and Prosensa today conceded defeat in the Phase III study for drisapersen, one of two closely-watched therapies for Duchenne muscular dystrophy which had ...

Training Execs from Top Medical Device and Diagnostic Companies to Host Annual Medical Sales Trainer Summit

barbara.lempert Event topics will focus on ACA, Learning Metrics and ROI, Patient and Product Outcomes, e-Learning, mHealth, Global Sales Education, and the role of Sales Trainers ROANOKE, ...
Page 5 of 14« First...34567...10...Last »
© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS